Abstract
We have previously demonstrated that both endomorphin-1 (EM-1) and endomorphin-2 (EM-2) at high doses (1.75–35 nmol) given intrathecally (i.t.) or intracerebroventricularly produce antinociception by stimulation of μ-opioid receptors. Now, we report that EM-2 at small doses (0.05–1.75 nmol), which injected alone did not produce antinociception, produces anti-analgesia against opioid agonist-induced antinociception. The tail-flick (TF) response was used to test the antinociception in male CD-1 mice. Intrathecal pretreatment with EM-2 (0.02–1.75 nmol) 45 min before i.t. morphine (3.0 nmol) injection dose dependently attenuated morphine-induced TF inhibition. On the other hand, a similar dose of EM-1 (1.64 nmol) failed to produce any antianalgesic effect. The EM-2 (1.75 nmol)-produced anti-analgesia against morphine-induced TF inhibition was blocked by i.t. pretreatment with the μ-opioid antagonist naloxone or 3-methoxynaltrexone, but not δ-opioid receptor antagonist naltrindole, κ-opioid receptor antagonist nor-binaltorphimine, or N-methyl-d-aspartate (NMDA) receptor antagonist MK-801. The EM-2-induced antianalgesic effect against morphine-induced TF inhibition was blocked by i.t. pretreatment with antiserum against dynorphin A(1-17), but not β-endorphin, [Met]-enkephalin, [Leu]-enkephalin, or cholecystokinin antiserum (200 μg each). The i.t. EM-2 pretreatment also attenuated the TF inhibition induced by other μ-opioid agonists, [d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin, EM-1 and EM-2, δ-opioid agonist deltorphin II, and κ-opioid agonist (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methane-sulfonate hydrate (U50,488H). It is concluded that EM-2 at subanalgesic doses presumably stimulates a subtype of μ-opioid receptor and subsequently induces the release of dynorphin A(1-17) to produce antianalgesic effects against μ-, δ-, or κ-agonists-induced antinociception. The EM-2-induced antianalgesia is not mediated by the release of [Met]-enkephalin, [Leu]-enkephalin, β-endorphin, or cholecystokinin, nor does it involve κ- or δ-opioid or NMDA receptors in the spinal cord.
Footnotes
-
This work was supported by Grant DA 03811 from the National Institute of Health, National Institute on Drug Abuse (to L.F.T.). A preliminary report of these results was presented at the 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 8–12, 2003.
-
DOI: 10.1124/jpet.103.056242.
-
ABBREVIATIONS: EM-1, endomorphin-1; EM-2, endomorphin-2; TF, tail-flick response; Dyn, dynorphin A(1-17); nor-BNI, nor-binaltorphimine; %MPE, percent maximum possible effect; NTI, naltrindole; NMDA, N-methyl-d-aspartate; MK-801, (–)-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine maleate; CCK, cholecystokinin; NRS, normal rabbit serum; U50,488H, (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methane-sulfonate hydrate; DAMGO, [d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin; ANOVA, analysis of variance.
- Received June 27, 2003.
- Accepted September 5, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|